Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$6.07
-0.09 (-1.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-37.8M · quality 21.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
86.7x
↑EV/EBITDA
28.2x
↑ROE
4.0%
↑Gross Margin
85.4%
↑Debt/Equity
18.85
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+70.7%
FCF CAGR
—
FCF margin
9.6%
FCF / Net income
50.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $291.8M · net income $554000.0 · FCF $27.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $291.8M | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.2M |
| Net Income | $554000.00 | $554000.00 | $-54.8M | $-62.3M | $-94.7M | $-122.7M | $-91.1M |
| EBITDA | $42.3M | $42.3M | $-14.0M | $-23.7M | $-69.3M | $-113.8M | $-82.1M |
| EPS | — | — | -0.37 | -0.45 | -0.70 | -1.55 | — |
| Gross Margin | 85.4% | 85.4% | 81.9% | 82.5% | 79.5% | — | — |
| Operating Margin | 8.5% | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -414.5% |
| Net Margin | 0.2% | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -452.2% |
| Balance Sheet | |||||||
| Debt/Equity | 18.85 | 18.85 | -9.17 | -33.79 | 4.38 | 0.92 | 2.58 |
| Current Ratio | 2.12 | 2.12 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $27.9M | $27.9M | $-37.8M | $-49.3M | $-103.4M | $-96.6M | $-80.9M |
| Returns | |||||||
| ROE | 4.0% | 4.0% | 185.2% | 917.9% | -209.5% | -128.9% | -270.0% |
| Valuation | |||||||
| P/E | 86.71 | 86.71 | — | — | — | — | — |
| EV/EBITDA | 28.24 | 28.24 | — | — | — | — | — |
| P/B | 76.60 | 76.60 | — | — | 3.15 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 43.7% | 43.7% | 23.9% | 48.7% | — | 146.0% | — |
| EPS Growth | — | — | 17.8% | 35.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.37 → n/d
Residual
+22.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.